Infectious Disease Special Edition
ISSUE: MARCH 2011 VOLUME: 1
OraSure Technologies, Inc. has received FDA approval for its OraQuick HCV Rapid Antibody Test, which detects HCV antibodies with a fingerstick whole blood sample.
The fingerstick whole blood claim is the second application to be approved by the FDA for the OraQuick HCV test. The first product, approved in June 2010, required venous whole blood specimens.
The OraQuick HCV Rapid Antibody Test is the first FDA-approved rapid, point-of-care test to detect antibodies to hepatitis C virus. This test eliminates the need to draw blood and provides results in 20 minutes, which may allow healthcare providers to identify more individuals infected with hepatitis C.
OraSure is partnering with Merck & Co., through its predecessor Schering Plough Corp., to collaborate on the development and promotion of the OraQuick HCV test.
For more information, visit http://www.orasure.com/.
—Based on a press release from OraSure Technologies, Inc.
Source
No comments:
Post a Comment